Research programme: memantine reformulations - NeuroMolecular PharmaceuticalsAlternative Names: Memantine reformulations - NeuroMolecular
Latest Information Update: 21 Feb 2008
At a glance
- Originator NeuroMolecular Pharmaceuticals
- Class Amines; Analgesics; Antidementias; Antiparkinsonians; Antispastics; Antitussives; Organic bridged compounds; Small molecules
- Mechanism of Action NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 21 Feb 2008 NeuroMolecular Pharmaceuticals is seeking partnership opportunities for this research programme (http://www.neuromolecular.com)